Need help finding what you are looking for?
Contact Us
PUBLISHER: Roots Analysis | PRODUCT CODE: 1643961
PUBLISHER: Roots Analysis | PRODUCT CODE: 1643961
Anti-Obesity Drugs Market by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players: Industry Trends and Global Forecasts, till 2035
PUBLISHED:
PAGES: 240 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
ANTI-OBESITY DRUGS MARKET:
As per Roots Analysis, the global anti-obesity drugs market size is estimated to grow from USD 12.8 billion in the current year to USD 104.9 billion by 2035, at a CAGR of 21.1% during the forecast period, till 2035.
The opportunity for anti-obesity drugs market has been distributed across the following segments:
- Type of Molecule
- Biologics
- Small Molecules
- Active Compound Used
- Tirzepatide
- Semaglutide
- Retatrutide
- Survodutide
- Cagrilintide and Semaglutide
- Orforglipron
- Liraglutide
- Other Active Compounds
- Mechanism of Action
- GLP-1 Agonist / GIP Agonist
- GLP-1 Agonist / GCGR Agonist
- GLP-1 Agonist
- GLP-1 Agonist / Amylin Analogue
- GLP-1 / GCGR / GIP Agonist
- Other Mechanisms of Action
- Type of Agonist
- Single-Agonist
- Dual-Agonist
- Tri-Agonist
- Action Pathway
- Centrally Acting
- Peripherally Acting
- Centrally Acting and Peripherally Acting
- Route of Administration
- Oral
- Parenteral
- Geographical Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Sales Forecast
- Contrave / Mysimba
- Feisumei
- Imcivree
- LOMAIRA
- QSYMIA
- Saxenda
- Wegovy / Ozempic
- Zepbound / Mounjaro
- BI 456906
- CagriSema
- HM11260C
- HRS-9531
- IBI362
- LM-008
- LY3437943
- LY3502970
- TG103
- Semaglutide 7.2 mg (Subcutaneous)
- Semaglutide (Oral)
- XW003
- Key Players
ANTI-OBESITY DRUGS MARKET: GROWTH AND TRENDS
Obesity is a chronic disease, which is characterized by the extreme accumulation of body fat, posing significant health risks to individuals. According to the World Health Organization, obesity is the fifth-leading cause of mortality worldwide. In order to curb this growing concern, various medications are currently available in the market or are being investigated across different phases of development.
Anti-obesity drugs, also referred to as weight loss drugs, include several pharmaceutical treatments designed specifically to assist individuals aiming to manage obesity and treat associated concerns, such as diabetes mellitus and cardiovascular disorders. These drugs work through several mechanisms, including appetite suppression, inhibition of fat absorption, and enhancement of metabolic rate. The selection of appropriate anti-obesity drugs is tailored to each patient's profile, taking into account their co-morbidities and potential risks to metabolic functions, as determined by healthcare professionals. Additionally, the development of novel compounds coupled with ongoing advancements in drug formulation and delivery systems, have led to the emergence of more effective and safer anti-obesity medications.
With rising global obesity rates and increased awareness of the associated health risks including diabetes, cardiovascular diseases, and certain cancers, the demand for effective anti-obesity drugs has surged. Moreover, with a growing emphasis on long-term management of obesity, the anti-obesity drugs market is poised to grow significantly, thus offering significant opportunities to stakeholders in the coming years.
ANTI-OBESITY DRUGS MARKET: KEY INSIGHTS
The report delves into the current state of the anti-obesity market and identifies potential growth opportunities within the industry. The key takeaways of the report are:
1.Currently, close to 225 drugs are marketed / being developed for the management of obesity; around 50% of these can be administered through oral route
2.A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; majority of these partnerships (~30%) were research and development agreements
3.The growing awareness among patients about the health risks, associated with obesity coupled with its increasing prevalence, is driving the anti-obesity market and positioning it for steady growth in the foreseeable future
4.The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 21.1%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035
5.Currently, the centrally acting anti-obesity drugs dominate the market; notably, parenteral route of administration is expected to capture the majority share (~85%) in market by 2035
ANTI-OBESITY DRUGS MARKET: KEY SEGMENTS
Small Molecules is the Fastest Growing Segment of the Anti-obesity Drugs Market
Based on the type of molecule, the global market for anti-obesity is segmented into biologics and small molecules. Currently, the small molecules segment occupies the highest share in the overall market. However, the landscape is likely to evolve as biologics emerge as a promising and more effective alternative that can target the underlying biological pathways associated with obesity.
Semaglutide is Likely to Hold the Largest Share of the Anti-obesity Drugs Market During the Forecast Period
Based on the active compound used, the global market for anti-obesity is segmented into Tirzepatide, Semaglutide, Retatrutide, Survodutide, Cagrilintide and Semaglutide, Orforglipron, Liraglutide, and other active compounds. Currently, Semaglutide leads the anti-obesity drugs market, and this can be attributed to its strong efficacy in weight management and diabetes control. However, owing to significant research progress, tirzepatide has gained attention for its dual action as both a GLP-1 and GIP receptor agonist, demonstrating superior weight loss results in clinical trials.
Anti-Obesity Drugs Market for GLP-1 agonist is Likely to Grow at a Relatively Faster Pace During the Forecast Period
Based on the mechanism of action, the global market for anti-obesity is segmented across GLP-1 agonist / GIP agonist, GLP-1 agonist / GCGR agonist, GLP-1 agonist, GLP-1 agonist / amylin analogue, GLP-1 / GCGR / GIP agonist and other mechanisms of action. Presently, the market is dominated by GLP-1 agonists, due to their ability to mimic hormone glucagon-like peptide 1 (GLP-1), thereby promoting significant weight loss.
Anti-Obesity Drugs Market for Single Agonist is Likely to Grow at a Higher CAGR During the Forecast Period
Based on the type of agonist, the global market for anti-obesity is segmented into single-agonist, dual-agonist and tri-agonist. Currently, single agonist captures the maximum anti-obesity drugs market share owing to its user-friendliness for facilitating patient adherence.
Anti-Obesity Drugs Catering to Centrally Acting Pathways is Likely to Dominate the Anti-Obesity Drugs Market During the Forecast Period
Based on the action pathway, the global market for anti-obesity is distributed across centrally acting, peripherally acting and, centrally and peripherally acting pathways. Presently, centrally acting segment captures the highest anti-obesity drugs market share and is expected to dominate the market during the forecast period. It is important to note that despite ongoing research into alternative pathways, robust clinical evidence supporting the efficacy of centrally acting agents ensures their continued dominance in the market.
Parenteral Route Hold the Largest Share of the Anti-Obesity Drugs Market
Based on the routes of administration, the global market for anti-obesity is segmented into oral and parenteral. Currently, the parenteral route captures the majority share of the market, owing to its rapid onset of action and higher bioavailability compared to oral formulations.
North America Accounts for the Largest Share of the Market
Based on geographical regions, the market is segmented into North America, Europe, Asia-Pacific, and Latin America. In the current scenario, North America is likely to capture the largest market share. This can be attributed to a high prevalence of obesity and related comorbidities, driving the demand for effective treatment options. Additionally, the region benefits from advanced healthcare infrastructure, significant investment in pharmaceutical research, and robust regulatory frameworks that facilitate the development and approval of new therapies.
Example Players in the Anti-Obesity Drugs Market
- Eli Lilly
- Pfizer
- Regeneron
- Kallyope
- CinFina Pharma
- Viking Therapeutics
- AstraZeneca
- Novo Nordisk
- Roche
- Adocia
- Boehringer Ingelheim
- Zealand Pharma
- Hanmi Pharm
- Jiangsu Hengrui Pharmaceuticals
- Gmax Biopharma
- PegBio
- QL Biopharm
- Sciwind Biosciences
ANTI-OBESITY DRUGS MARKET: RESEARCH COVERAGE
The report on anti-obesity drugs market features insights on various sections, including:
- Market Sizing and Opportunity Analysis: An in-depth analysis of current market opportunity and the future growth potential of anti-obesity drugs market, focusing on key market segments, including [A] type of molecule, [B] active compound used, [C] mechanism of action, [D] type of agonist, [E] action pathway, [F] route of administration, and [G] geographical regions.
- Market Impact Analysis: A thorough analysis of various factors, such as [A] drivers, [B] restraints, [C] opportunities, and [D] existing challenges that are likely to impact market growth.
- Market Landscape: A comprehensive evaluation of companies engaged in anti-obesity domain, based on several relevant parameters, such as [A] stage of development, [B] type of molecule, [C] mechanism of action, [D] type of agonist, [E] route of administration, [F] dosage frequency, and [G] type of therapy.
- Anti-obesity Drug Developer Landscape: The report features a list of players engaged in the anti-obesity drug domain, along with analyses based on [A] year of establishment, [B] company size, and [C] location of headquarters, and [D] most active players.
- Company Profiles: In-depth profiles of key industry players in the anti-obesity drug domain, featuring information on [A] company overview, [B] financial information (if available), [C] metaverse in healthcare portfolio, [D] recent developments, and [E] future outlook statements.
- Big Pharma Players: An insightful review of various anti-obesity initiatives undertaken by big pharma players, highlighting trends across various parameters, such as [A] year of initiative, [B] type of initiative, [C] number of partnerships, [D] type of partnership, and [E] type of expansion.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 10% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
Product Code: RA100519
TABLE OF CONTENTS
1. BACKGROUND
- 1.1. Context
- 1.2. Project Objectives
2. RESEARCH METHODOLOGY
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Factors
- 2.6.1. Demographics
- 2.6.2. Economic Factors
- 2.6.3. Competitive Landscape
- 2.6.4. Government Regulations and Healthcare Policies
- 2.6.5. R&D Investment
- 2.6.6. Technological Factors
- 2.6.7. Industry Consolidation
- 2.6.8. Supply Chain
- 2.6.9. Market Access
- 2.6.10. COVID Impact / Related Factors
- 2.6.11. Market Access
- 2.6.12. COVID Impact / Related Factors
- 2.6.13. Patient Advocacy and Influence
- 2.6.14. Healthcare Infrastructure
3. MARKET DYNAMICS
- 3.1. Chapter Overview
- 3.2. Forecast Methodology
- 3.2.1. Top-Down Approach
- 3.2.2. Botton-Up Approach
- 3.2.3. Hybrid Approach
- 3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
- 3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
- 3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
- 3.6. Key Market Segments
- 3.7. Robust Quality Control
- 3.8. Limitations
4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
- 4.1. Chapter Overview
- 4.2. Market Dynamics
- 4.2.1. Time Period
- 4.2.1.1. Historical Trends
- 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
- 4.2.2.1. Overview of Major Currencies Affecting the Market
- 4.2.2.2. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Exchange Impact
- 4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
- 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
- 4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 4.2.5. Inflation
- 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
- 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.1. Time Period
5. EXECUTIVE SUMMARY
6. INTRODUCTION
- 6.1. Overview of Anti-Obesity Drugs
- 6.2. Health Risks Linked with Long-term Obesity
- 6.3. Currently Approved Anti-Obesity Drug Classes
- 6.4. Challenges Associated with Anti-Obesity Drugs
- 6.5. Future Perspectives
7. MARKET LANDSCAPE: ANTI-OBESITY DRUGS
- 7.1. Market Landscape: Anti-Obesity Drugs
- 7.1.1. Analysis by Status of Development
- 7.1.2. Analysis by Type of Molecule
- 7.1.3. Analysis by Mechanism of Action
- 7.1.4. Analysis by Type of Agonist
- 7.1.5. Analysis by Route of Administration
- 7.1.6. Analysis by Dosage Frequency
- 7.1.7. Analysis by Type of Therapy
- 7.2. Developer Landscape: Anti-Obesity Drugs
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters
- 7.2.4. Analysis by Headquarters (Country) and Status of Development
- 7.2.5. Most Active Developers: Analysis by Number of Drug Candidates
8. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN NORTH AMERICA
- 8.1. Chapter Overview
- 8.2. Detailed Company Profiles
- 8.2.1. Eli Lilly
- 8.2.1.1. Company Details
- 8.2.1.2. Pipeline Portfolio
- 8.2.1.3. Financial Details
- 8.2.1.4. Recent Developments and Future Outlook
- 8.2.2. Pfizer
- 8.2.3. Regeneron
- 8.2.1. Eli Lilly
- 8.3. Brief Company Profiles
- 8.3.1. CinFina Pharma
- 8.3.1.1. Company Details
- 8.3.1.2. Pipeline Portfolio
- 8.3.2. Kallyope
- 8.3.3. Viking Therapeutics
- 8.3.1. CinFina Pharma
9. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN EUROPE
- 9.1. Chapter Overview
- 9.2. Detailed Company Profiles
- 9.2.1. AstraZeneca
- 9.2.1.1. Company Details
- 9.2.1.2. Pipeline Portfolio
- 9.2.1.3. Financial Details
- 9.2.1.4. Recent Developments and Future Outlook
- 9.2.2. Novo Nordisk
- 9.2.3. Roche
- 9.2.1. AstraZeneca
- 9.3. Brief Company Profiles
- 9.3.1. Adocia
- 9.3.1.1. Company Details
- 9.3.1.2. Pipeline Portfolio
- 9.3.2. Boehringer Ingelheim
- 9.3.3. Zealand Pharma
- 9.3.1. Adocia
10. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD
- 10.1. Chapter Overview
- 10.2. Detailed Company Profiles
- 10.2.1. Hanmi Pharmaceuticals
- 10.2.1.1. Company Details
- 10.2.1.2. Pipeline Portfolio
- 10.2.1.3. Financial Details
- 10.2.1.4. Recent Developments and Future Outlook
- 10.2.2. Jiangsu Hengrui Pharmaceuticals
- 10.2.1. Hanmi Pharmaceuticals
- 10.3. Brief Company Profiles
- 10.3.1. Gmax Biopharma
- 10.3.1.1. Company Details
- 10.3.1.2. Pipeline Portfolio
- 10.3.2. PegBio
- 10.3.3. QL Biopharm
- 10.3.4. Sciwind Biosciences
- 10.3.1. Gmax Biopharma
11. BIG PHARMA INITIATIVES
- 11.1. Methodology
- 11.2. Big Pharma Players: Anti-obesity focused Initiatives
- 11.2.1. Analysis of Big Pharma Players by Number of Initiatives
- 11.2.2. Analysis by Year of Initiative
- 11.2.3. Analysis by Big Pharma Player by Year of Initiative and Number of Initiatives
- 11.2.4. Analysis by Type of Initiative
- 11.2.5. Analysis by Year and Type of Initiative
- 11.2.6. Analysis by Big Pharma Player and Type of Initiative
- 11.2.7. Analysis by Big Pharma Player and Number of Partnerships
- 11.2.8. Analysis by Type of Partnership
- 11.2.9. Analysis by Type of Expansion
- 11.2.10. Analysis by Big Pharma Player by Region and Number of Initiatives
- 11.2.11. Benchmarking of Big Pharma Players
12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
- 12.1. Chapter Overview
- 12.2. Market Drivers
- 12.3. Market Restraints
- 12.4. Market Opportunities
- 12.5. Market Challenges
13. GLOBAL ANTI-OBESITY DRUGS MARKET
- 13.1. Forecast Methodology and Key Assumptions
- 13.2. Global Anti-Obesity Drugs Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
- 13.2.1. Scenario Analysis
- 13.2.1.1. Conservative Scenario
- 13.2.1.2. Optimistic Scenario
- 13.2.1. Scenario Analysis
- 13.3. Key Market Segmentations
14. ANTI-OBESITY DRUGS MARKET, BY TYPE OF MOLECULE
- 14.1. Anti-Obesity Drugs Market: Distribution by Type of Molecule
- 14.1.1. Anti-Obesity Drugs Market for Biologics, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 14.1.2. Anti-Obesity Drugs Market for Small Molecules, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
15. ANTI-OBESITY DRUGS MARKET, BY ACTIVE COMPOUND USED
- 15.1. Anti-Obesity Drugs Market: Distribution by Active Compound Used
- 15.1.1. Anti-Obesity Drugs Market for Tirzepatide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 15.1.2. Anti-Obesity Drugs Market for Semaglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 15.1.3. Anti-Obesity Drugs Market for Retatrutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 15.1.4. Anti-Obesity Drugs Market for Survodutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 15.1.5. Anti-Obesity Drugs Market for Cagrilintide and Semglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 15.1.6. Anti-Obesity Drugs Market for Orforglipron, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 15.1.7. Anti-Obesity Drugs Market for Liraglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 15.1.8. Anti-Obesity Drugs Market for other active compounds used, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION
- 16.1. Anti-Obesity Drugs Market: Distribution by Mechanism of Action
- 16.1.1. Anti-Obesity Drugs Market for GLP-1 Agonist / GIP Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 16.1.2. Anti-Obesity Drugs Market for GLP-1 Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 16.1.3. Anti-Obesity Drugs Market for GLP-1 Agonist / GCGR Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 16.1.4. Anti-Obesity Drugs Market for GLP-1 / GCGR / GIP Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 16.1.5. Anti-Obesity Drugs Market for GLP-1 Agonist / Amylin Analogue, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 16.1.6. Anti-Obesity Drugs Market for Other Mechanisms of Action, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17. ANTI-OBESITY DRUGS MARKET, BY TYPE OF AGONIST
- 17.1. Anti-Obesity Drugs Market: Distribution by Type of Agonist
- 17.1.1. Anti-Obesity Drugs Market for Single-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 17.1.2. Anti-Obesity Drugs Market for Dual-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 17.1.3. Anti-Obesity Drugs Market for Tri-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
18. ANTI-OBESITY DRUGS MARKET, BY ACTION PATHWAY
- 18.1. Anti-Obesity Drugs Market: Distribution by Action Pathway
- 18.1.1. Anti-Obesity Drugs Market for Centrally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 18.1.2. Anti-Obesity Drugs Market for Peripherally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 18.1.3. Anti-Obesity Drugs Market for Centrally Acting and Peripherally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
19. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 19.1. Anti-Obesity Drugs Market: Distribution by Route of Administration
- 19.1.1. Anti-Obesity Drugs Market for Oral Administration, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 19.1.2. Anti-Obesity Drugs Market for Parenteral Administration, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
20. ANTI-OBESITY DRUGS MARKET, BY GEOGRAPHICAL REGIONS
- 20.1. Anti-Obesity Drugs Market: Distribution by Geographical Regions
- 20.1.1. Anti-Obesity Drugs Market in North America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 20.1.2. Anti-Obesity Drugs Market in Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 20.1.3. Anti-Obesity Drugs Market in Asia-Pacific, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
- 20.1.4. Anti-Obesity Drugs Market in Latin America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
21. ANTI-OBESITY DRUGS MARKET, SALES FORECAST OF MARKETED AND PHASE III DRUGS
- 21.1. Marketed Drugs: Sales Forecast
- 21.1.1. Contrave / Mysimba (Naltrexone, Bupropion)
- 21.1.2. Feisumei (Beinaglutide)
- 21.1.3. Imcivree (Setmelanotide)
- 21.1.4. LOMAIRA (Phentermine Hydrochloride)
- 21.1.5. QSYMIA (Phentermine and Topiramate)
- 21.1.6. Saxenda (Liraglutide)
- 21.1.7. Wegovy / Ozempic (Semaglutide)
- 21.1.8. Zepbound / Mounjaro (Tirzepatide)
- 21.2. Phase III Drugs: Sales Forecast
- 21.2.1. BI 456906 (Survodutide)
- 21.2.2. CagriSema (Cagrilintide and Semaglutide)
- 21.2.3. HM11260C (Efpeglenatide)
- 21.2.4. HRS-9531
- 21.2.5. IBI362 (Mazdutide)
- 21.2.6. LM-008
- 21.2.7. LY3437943 (Retatrutide)
- 21.2.8. LY3502970 (Orforglipron)
- 21.2.9. TG103
- 21.2.10. Semaglutide 7.2 mg (Subcutaneous)
- 21.2.11. Semaglutide (Oral)
- 21.2.12. XW003
22. ANTI-OBESITY DRUGS MARKET, BY KEY PLAYERS
- 22.1. Anti-Obesity Drugs Market: Distribution of Key Players
23. APPENDIX 1: TABULATED DATA
24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Product Code: RA100519
List of Tables
- Figure 2.1 Research Methodology: Project Methodology
- Figure 2.2 Research Methodology: Forecast Methodology
- Figure 3.1 Lessons Learnt from Past Recessions
- Figure 6.1 Health Risks Linked with Long-term Obesity
- Figure 6.2 Currently Approved Anti-Obesity Drug Classes
- Figure 7.1 Anti-Obesity Drugs: Distribution by Status of Development
- Figure 7.2 Anti-Obesity Drugs: Distribution by Type of Molecule
- Figure 7.3 Anti-Obesity Drugs: Distribution by Mechanism of Action
- Figure 7.4 Anti-Obesity Drugs: Distribution by Type of Agonist
- Figure 7.5 Anti-Obesity Drugs: Distribution by Route of Administration
- Figure 7.6 Anti-Obesity Drugs: Distribution by Dosage Frequency
- Figure 7.7 Anti-Obesity Drugs: Distribution by Type of Therapy
- Figure 7.8 Anti-Obesity Drug Developers: Distribution by Year of Establishment
- Figure 7.9 Anti-Obesity Drug Developers: Distribution by Company Size
- Figure 7.10 Anti-Obesity Drug Developers: Distribution by Location of Headquarters
- Figure 7.11 Anti-Obesity Drug Developers: Distribution by Headquarters (Country) and Status of Development
- Figure 7.12 Most Active Developers: Distribution by Number of Drug Candidates
- Figure 8.1 Eli Lilly: Annual Revenues (USD Billion)
- Figure 8.2 Pfizer: Annual Revenues (USD Billion)
- Figure 8.3 Regeneron: Annual Revenues (USD Billion)
- Figure 9.1 AstraZeneca: Annual Revenues (USD Billion)
- Figure 9.2 Novo Nordisk: Annual Revenues (DKK Billion)
- Figure 9.3 Roche: Annual Revenues (CHF Billion)
- Figure 10.1 Hanmi Pharmaceuticals: Annual Revenues (KRW Billion)
- Figure 10.2 Jiangsu Hengrui Pharmaceuticals: Annual Revenues (CNY Billion)
- Figure 11.1 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
- Figure 11.2 Big Pharma Initiatives: Distribution by Year of Initiative
- Figure 11.3 Big Pharma Initiatives: Distribution by Big Pharma Players by Year and Number of Initiatives
- Figure 11.4 Big Pharma Initiatives: Distribution by Type of Initiative
- Figure 11.5 Big Pharma Initiatives: Distribution by Year and Type of Initiative
- Figure 11.6 Big Pharma Initiatives: Distribution by Big Pharma Players and Type of Initiative
- Figure 11.7 Big Pharma Initiatives: Distribution by Type of Partnership
- Figure 11.8 Big Pharma Initiatives: Distribution by Type of Expansion
- Figure 11.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Region and Number of Initiatives
- Figure 11.10 Benchmarking of Big Pharma Players
- Figure 12.1 Anti-Obesity Drugs: Market Drivers
- Figure 12.2 Anti-Obesity Drugs: Market Restraints
- Figure 12.3 Anti-Obesity Drugs: Market Opportunities
- Figure 12.4 Anti-Obesity Drugs: Market Challenges
- Figure 13.1 Global Anti-Obesity Drug Market, Historical Trends (Since 2019) and Forecasted Estimates (till 2035)
- Figure 13.2 Global Anti-obesity Drugs Market, till 2035 (USD Billion) (USD Billion): Conservative Scenario
- Figure 13.3 Global Anti-obesity Drugs Market, till 2035 (USD Billion) (USD Billion): Optimistic Scenario
- Figure 14.1 Anti-obesity Drugs Market: Distribution by Type of Molecule
- Figure 14.2 Anti-obesity Market for Biologics, till 2035 (USD Billion)
- Figure 14.3 Anti-obesity Market for Small Molecules, till 2035 (USD Billion)
- Figure 15.1 Anti-obesity Drugs Market: Distribution by Active Compound Used
- Figure 15.2 Anti-obesity Market for Tirzepatide, till 2035 (USD Billion)
- Figure 15.3 Anti-obesity Market for Semaglutide, till 2035 (USD Billion)
- Figure 15.4 Anti-obesity Market for Retatrutide, till 2035 (USD Billion)
- Figure 15.5 Anti-obesity Market for Survodutide, till 2035 (USD Billion)
- Figure 15.6 Anti-obesity Market for Cagrilintide / Semaglutide, till 2035 (USD Billion)
- Figure 15.7 Anti-obesity Market for Orforglipron, till 2035 (USD Billion)
- Figure 15.8 Anti-obesity Market for Liraglutide, till 2035 (USD Billion)
- Figure 15.9 Anti-obesity Market for Other Compounds, till 2035 (USD Billion)
- Figure 16.1 Anti-obesity Drugs Market: Distribution by Mechanism of Action
- Figure 16.2 Anti-obesity Market for GLP-1 Agonist / GIP Agonist, till 2035 (USD Billion)
- Figure 16.3 Anti-obesity Market for GLP-1 Agonist, till 2035 (USD Billion)
- Figure 16.4 Anti-obesity Market for GLP-1 / GCGR / GIP Agonist, till 2035 (USD Billion)
- Figure 16.5 Anti-obesity Market for GLP-1 Agonist / GCGR Agonist, till 2035 (USD Billion)
- Figure 16.6 Anti-obesity Market for GLP-1 Agonist / Amylin Analogue, till 2035 (USD Billion)
- Figure 16.7 Anti-obesity Market for Other Mechanisms of Action, till 2035 (USD Billion)
- Figure 17.1 Anti-obesity Market: Distribution by Type of Agonist
- Figure 17.2 Anti-obesity Market for Single-Agonist, till 2035 (USD Billion)
- Figure 17.3 Anti-obesity Market for Dual-Agonist, till 2035 (USD Billion)
- Figure 17.4 Anti-obesity Market for Tri-Agonist, till 2035 (USD Billion)
- Figure 18.1 Anti-obesity Drugs Market: Distribution by Action Pathway
- Figure 18.2 Anti-obesity Market for Centrally Acting Drugs, till 2035 (USD Billion)
- Figure 18.3 Anti-obesity Market for Peripherally Acting Drugs, till 2035 (USD Billion)
- Figure 18.4 Anti-obesity Market for Centrally and Peripherally Acting Drugs, till 2035 (USD Billion)
- Figure 19.1 Anti-obesity Drugs Market: Distribution by Route of Administration
- Figure 19.2 Anti-obesity Market for Parenteral Administration, till 2035 (USD Billion)
- Figure 19.3 Anti-obesity Market for Oral Administration, till 2035 (USD Billion)
- Figure 20.1 Anti-obesity Drugs Market: Distribution by Geographical Regions
- Figure 20.2 Anti-obesity Market in North America, till 2035 (USD Billion)
- Figure 20.3 Anti-obesity Market in North America (country-wise), till 2035 (USD Billion)
- Figure 20.4 Anti-obesity Market in Europe, till 2035 (USD Billion)
- Figure 20.5 Anti-obesity Market in Europe (country-wise), till 2035 (USD Billion)
- Figure 20.6 Anti-obesity Market in Asia-Pacific, till 2035 (USD Billion)
- Figure 20.7 Anti-obesity Market in Asia-Pacific (country-wise), till 2035 (USD Billion)
- Figure 20.8 Anti-obesity Market in Latin America, till 2035 (USD Billion)
- Figure 20.9 Anti-obesity Market in Latin America (country-wise), till 2035 (USD Billion)
- Figure 21.1 Contrave / Mysimba (Naltrexone, Bupropion) Sales Forecast, till 2035 (USD Billion)
- Figure 21.2 Feisumei (Beinaglutide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.3 Imcivree (Setmelanotide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.4 LOMAIRA (Phentermine Hydrochloride) Sales Forecast, till 2035 (USD Billion)
- Figure 21.5 QSYMIA (Phentermine and Topiramate) Sales Forecast, till 2035 (USD Billion)
- Figure 21.6 Saxenda (Liraglutide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.7 Wegovy / Ozempic (Semaglutide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.8 Zepbound / Mounjaro (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.9 BI 456906 (Survodutide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.10 CagriSema (Cagrilintide and Semaglutide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.11 HM11260C (Efpeglenatide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.12 HRS-9531 Sales Forecast, till 2035 (USD Billion)
- Figure 21.13 IBI362 (Mazdutide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.14 LM-008 Sales Forecast, till 2035 (USD Billion)
- Figure 21.15 LY3437943 (Retatrutide) Sales Forecast, till 2035 (USD Billion)
- Figure 21.16 LY3502970 (Orforglipron) Sales Forecast, till 2035 (USD Billion)
- Figure 21.17 TG103 Sales Forecast, till 2035 (USD Billion)
- Figure 21.18 Semaglutide 7.2 mg (Subcutaneous) Sales Forecast, till 2035 (USD Billion)
- Figure 21.19 Semaglutide (Oral) Sales Forecast, till 2035 (USD Billion)
- Figure 21.20 XW003 Sales Forecast, till 2035 (USD Billion)
- Figure 22.1 Anti-obesity Drugs Market: Distribution by Key Players, 2020 (USD Billion)
- Figure 22.2 Anti-obesity Drugs Market: Distribution by Key Players, Current Year (USD Billion)
- Figure 22.3 Anti-obesity Drugs Market: Distribution by Key Players, 2035 (USD Billion)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.